Tessellate BIO Welcomes Lara Boyd as New Chief Business Officer
Tessellate BIO, a preclinical stage biotechnology firm specializing in innovative Synthetic Lethality approaches, has announced the appointment of Dr. Lara Boyd as the new Chief Business Officer. This strategic move is expected to pave the way for enhanced business development efforts and greater outreach in the biotech industry.
Dr. Lara Boyd's Extensive Experience
Dr. Lara Boyd joins Tessellate BIO with a wealth of experience gained from her time at F-star Therapeutics. At F-star, she held multiple senior roles, culminating in her position as Vice President Head of Business Development and Corporate Strategy. Her responsibilities there included overseeing comprehensive business development activities. Before her tenure at F-star, Dr. Boyd played key roles at Cancer Research Technology and Cancer Research UK, where she further honed her skills in the biotechnology landscape.
Academic Background
Dr. Boyd completed her PhD at the esteemed MRC Genome Damage and Stability Centre, a respected institution known for its focus on cancer research. She then carried out post-doctoral research at the Barts Cancer Institute, further deepening her expertise in this vital area of health science.
Leadership's Confidence in Dr. Boyd
Andree Blaukat, the CEO of Tessellate BIO, expressed his enthusiasm about Dr. Boyd’s appointment, stating, "Lara brings exceptionally strong and relevant experience to Tessellate BIO, with a proven track record in business development and background in cancer research. I have no doubt she will add considerable strength to our leadership team as we continue our rapid growth and development." This endorsement underscores the confidence the company has in Dr. Boyd’s capabilities.
Dr. Boyd's Vision
Expressing her excitement about joining Tessellate BIO, Dr. Boyd stated, "I am hugely excited to be joining Tessellate BIO. The development of new treatments for cancer has driven my career both in research and in business, and Tessellate BIO's approach to precision medicine represents an enormous opportunity for patients whose needs are not being met by current medicines." Her commitment to advancing cancer treatment aligns perfectly with the company’s mission.
The Mission of Tessellate BIO
Tessellate BIO operates with a clear mission: to discover and develop innovative precision oncology medicines meant to turn cancer patients into cancer survivors. As a private biotechnology company in the preclinical stage, it is at the forefront of redefining Synthetic Lethality and developing drugs that address complex and underexplored cancer pathways.
Innovative Strategies for Drug Development
The firm’s strategy focuses on small molecule drug discovery aimed at new, validated oncology targets. This involves the parallel development of companion diagnostics, including a potentially best-in-class diagnostic tool designed to detect ALT positive cancers, which can identify patients suitable for treatment. The approach demonstrates Tessellate BIO's commitment to precision medicine.
Research and Development
Supported by an experienced team of drug hunters, Tessellate BIO is working diligently to build a diverse pipeline of first-in-class medicines. Their research is backed by significant partnerships with internationally recognized laboratories and institutions, including the Children’s Medical Research Institute in Australia and the Instituto de Medicina Molecular in Portugal. These collaborative efforts are vital for advancing their lead program, which focuses on complexes essential for the ALT mechanism, specifically targeting the FANCM protein complex.
Company Headquarters and Funding
Tessellate BIO is headquartered in the Netherlands, with research facilities located at the Stevenage Bioscience Catalyst in the UK. The company receives support from leading life science investors, including BioGeneration Ventures and Forbion, which provides the necessary funding to continue its ambitious research and development efforts.
Frequently Asked Questions
Who is the new Chief Business Officer at Tessellate BIO?
Dr. Lara Boyd has recently been appointed as the Chief Business Officer at Tessellate BIO.
What is the focus of Tessellate BIO’s research?
Tessellate BIO focuses on developing novel precision oncology medicines and redefining Synthetic Lethality approaches for cancer treatment.
Where is Tessellate BIO headquartered?
Tessellate BIO is headquartered in the Netherlands, with research labs located at the Stevenage Bioscience Catalyst in the UK.
What experience does Dr. Lara Boyd bring to Tessellate BIO?
Dr. Boyd brings extensive experience in business development and cancer research from her previous roles at F-star Therapeutics and other organizations.
What is the company’s primary mission?
The mission of Tessellate BIO is to develop precision oncology medicines that turn cancer patients into cancer survivors.
